Adaptive Biotechnologies (ADPT) investor relations material

Mission and company overview

• Focuses on translating the genetic language of the adaptive immune system into clinical products for disease diagnosis and treatment.

• Founded in 2009, listed on NASDAQ in 2019, with over 630 employees and 430+ patents.

• Operates two main business segments: Minimal Residual Disease (MRD) diagnostics and Immune Medicine for drug discovery.

Technology and innovation

• Utilizes the adaptive immune system's genetic diversity to inform diagnostics and therapeutics.

• Developed proprietary sequencing and mapping technologies for TCR and BCR, enabling precise disease detection.

• Built a large-scale TCR-antigen data set, surpassing publicly available resources, to power AI-driven disease understanding.

MRD diagnostics business (clonoSEQ)

• clonoSEQ is FDA-cleared for MRD detection in multiple myeloma, ALL, and CLL, and CLIA-validated for DLBCL and MCL.

• Recognized as the gold standard in hematology MRD, with over 100,000 patients tested and payer coverage exceeding 300 million lives.

• Demonstrates superior sensitivity compared to flow cytometry, detecting residual disease missed by traditional methods.

• Supported by over 250 peer-reviewed publications and included in major clinical guidelines.

• Drives value for clinicians, patients, payers, and pharma, with significant cost savings and improved patient outcomes.